Celldex Therapeutics (NASDAQ:CLDX) Upgraded at Wolfe Research

Wolfe Research upgraded shares of Celldex Therapeutics (NASDAQ:CLDX) from a peer perform rating to an outperform rating in a report published on Monday morning, MarketBeat.com reports. Wolfe Research currently has $44.00 price objective on the biopharmaceutical company’s stock.

A number of other research analysts have also commented on CLDX. Stifel Nicolaus reiterated a “buy” rating and issued a $68.00 price target (up from $58.00) on shares of Celldex Therapeutics in a research note on Thursday, February 26th. Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Wednesday, January 21st. Barclays upped their target price on Celldex Therapeutics from $21.00 to $24.00 and gave the company an “underweight” rating in a research report on Wednesday, December 17th. Finally, The Goldman Sachs Group increased their target price on Celldex Therapeutics from $30.00 to $34.00 and gave the stock a “neutral” rating in a research note on Monday, March 2nd. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $44.45.

Celldex Therapeutics Price Performance

CLDX stock opened at $31.68 on Monday. Celldex Therapeutics has a one year low of $14.40 and a one year high of $34.52. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of -8.14 and a beta of 1.17. The company has a fifty day moving average price of $26.98 and a two-hundred day moving average price of $26.43.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.22). The company had revenue of $0.12 million during the quarter, compared to the consensus estimate of $1.53 million. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 41.67%. Research analysts anticipate that Celldex Therapeutics will post -2.48 EPS for the current fiscal year.

Hedge Funds Weigh In On Celldex Therapeutics

Hedge funds have recently bought and sold shares of the business. Aster Capital Management DIFC Ltd acquired a new stake in Celldex Therapeutics in the 3rd quarter worth about $26,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Celldex Therapeutics during the 3rd quarter worth approximately $42,000. Russell Investments Group Ltd. grew its position in shares of Celldex Therapeutics by 27.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 501 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Celldex Therapeutics during the third quarter worth approximately $63,000. Finally, Strs Ohio bought a new position in shares of Celldex Therapeutics during the third quarter worth approximately $75,000.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.

Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.